JP2025503177A5 - - Google Patents
Info
- Publication number
- JP2025503177A5 JP2025503177A5 JP2024544414A JP2024544414A JP2025503177A5 JP 2025503177 A5 JP2025503177 A5 JP 2025503177A5 JP 2024544414 A JP2024544414 A JP 2024544414A JP 2024544414 A JP2024544414 A JP 2024544414A JP 2025503177 A5 JP2025503177 A5 JP 2025503177A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- day
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304422P | 2022-01-28 | 2022-01-28 | |
| US63/304,422 | 2022-01-28 | ||
| PCT/EP2023/052005 WO2023144306A1 (en) | 2022-01-28 | 2023-01-27 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503177A JP2025503177A (ja) | 2025-01-30 |
| JP2025503177A5 true JP2025503177A5 (cg-RX-API-DMAC7.html) | 2026-02-10 |
Family
ID=85158380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544414A Pending JP2025503177A (ja) | 2022-01-28 | 2023-01-27 | びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230303693A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4469083A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503177A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240144239A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118647402A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023213099A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243347A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314341A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008832A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202345905A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023144306A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| BR112020015052A2 (pt) | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
| WO2022053654A1 (en) * | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
-
2023
- 2023-01-27 KR KR1020247028132A patent/KR20240144239A/ko active Pending
- 2023-01-27 JP JP2024544414A patent/JP2025503177A/ja active Pending
- 2023-01-27 WO PCT/EP2023/052005 patent/WO2023144306A1/en not_active Ceased
- 2023-01-27 IL IL314341A patent/IL314341A/en unknown
- 2023-01-27 EP EP23702969.9A patent/EP4469083A1/en active Pending
- 2023-01-27 AU AU2023213099A patent/AU2023213099A1/en active Pending
- 2023-01-27 US US18/160,391 patent/US20230303693A1/en active Pending
- 2023-01-27 MX MX2024008832A patent/MX2024008832A/es unknown
- 2023-01-27 US US18/833,267 patent/US20250101102A1/en active Pending
- 2023-01-27 CN CN202380019130.7A patent/CN118647402A/zh active Pending
- 2023-01-27 CA CA3243347A patent/CA3243347A1/en active Pending
- 2023-01-30 TW TW112103162A patent/TW202345905A/zh unknown